Cencora, Inc. (NYSE:COR) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Cencora, Inc. (NYSE:COR) by 3.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 90,767 shares of the company’s stock after acquiring an additional 2,711 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Cencora were worth $20,430,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of COR. New Millennium Group LLC acquired a new position in Cencora in the second quarter valued at $26,000. LRI Investments LLC purchased a new position in shares of Cencora during the first quarter worth about $31,000. MFA Wealth Advisors LLC purchased a new stake in Cencora during the 2nd quarter valued at approximately $30,000. Concord Wealth Partners acquired a new stake in Cencora during the 3rd quarter worth approximately $30,000. Finally, SYSTM Wealth Solutions LLC purchased a new position in shares of Cencora in the 2nd quarter valued at approximately $36,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

COR stock opened at $251.60 on Friday. The firm has a 50 day moving average of $234.91 and a 200-day moving average of $232.46. The company has a market cap of $49.58 billion, a price-to-earnings ratio of 33.50, a PEG ratio of 1.66 and a beta of 0.44. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a 12-month low of $195.83 and a 12-month high of $253.27.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, November 15th. This is a boost from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.87%. Cencora’s payout ratio is currently 29.29%.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the transaction, the chairman now owns 326,557 shares of the company’s stock, valued at $79,670,111.29. The trade was a 13.28 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have sold 93,018 shares of company stock worth $22,478,942. 15.80% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on COR shares. Barclays upped their price target on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Leerink Partners reduced their target price on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. Robert W. Baird boosted their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Finally, Bank of America reiterated a “neutral” rating and set a $245.00 target price (down previously from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $271.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.